Drug intelligence / Profile preview

TRIKE

Development stage: Preclinical
Lead developer: GT Biopharma
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptides, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

TRIKE is a tri-specific killer engager (TriKE) being developed by Ingenium Therapeutics for the treatment of solid tumors. As a tri-specific engager, the molecule is designed to simultaneously bind to tumor-associated antigens and engage cytotoxic effector cells, typically Natural Killer (NK) cells, to facilitate targeted tumor cell lysis. The specific molecular targets (antigens) and the exact binding domains for this asset have not been publicly disclosed by the company. TRIKE is currently in the proof-of-concept (PoC) or preclinical stage of development.

Other names: tri-specific killer engager

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FCGR3B (Fc gamma receptor III)

Beyond the preview

Go deeper on TRIKE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIKE.

Explore the full profile